Ninlaro, an oral multiple myeloma treatment that solves the problem of insurance benefits, is prescribed at general hospitals.

According to related industries, Ninlaro (Ixazomib), an oral medication option in the field of multiple myeloma (MM), is used in Korea, including Samsung Medical Center, Seoul National University Hospital, the Catholic University of Korea Seoul St. Mary's Hospital, Hwasun Chonnam National University Hospital, Kyungpook National University Hospital, Pusan ​​National University Hospital, and Chungnam National University Hospital. it has passed the drug commitee (DC) of major medical institutions nationwide.

Ninlaro was designated as an orphan drug in May